302 related articles for article (PubMed ID: 10231076)
1. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?
Gabriel SE; Kneeland TS; Melton LJ; Moncur MM; Ettinger B; Tosteson AN
Med Decis Making; 1999; 19(2):141-8. PubMed ID: 10231076
[TBL] [Abstract][Full Text] [Related]
2. Impact of hip and vertebral fractures on quality-adjusted life years.
Tosteson AN; Gabriel SE; Grove MR; Moncur MM; Kneeland TS; Melton LJ
Osteoporos Int; 2001 Dec; 12(12):1042-9. PubMed ID: 11846331
[TBL] [Abstract][Full Text] [Related]
3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
[TBL] [Abstract][Full Text] [Related]
5. Has the impact of hormone replacement therapy on health-related quality of life been undervalued?
Tosteson AN; Gabriel SE; Kneeland TS; Moncur MM; Manganiello PD; Schiff I; Ettinger B; Melton LJ
J Womens Health Gend Based Med; 2000 Mar; 9(2):119-30. PubMed ID: 10746515
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
Moriwaki K; Noto S
Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
[TBL] [Abstract][Full Text] [Related]
7. The psychometric properties of patient preferences in osteoporosis.
Cranney A; Coyle D; Pham BA; Tetroe J; Wells G; Jolly E; Tugwell P
J Rheumatol; 2001 Jan; 28(1):132-7. PubMed ID: 11196515
[TBL] [Abstract][Full Text] [Related]
8. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.
Borgström F; Johnell O; Kanis JA; Jönsson B; Rehnberg C
Osteoporos Int; 2006 Oct; 17(10):1459-71. PubMed ID: 16847588
[TBL] [Abstract][Full Text] [Related]
9. Health state utility values of osteoporotic fractures among Korean women.
Bae G; Kim E; Kwon HY; An J; Park J; Yang H
Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):177-183. PubMed ID: 31092075
[No Abstract] [Full Text] [Related]
10. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
Johnell O; Jönsson B; Jönsson L; Black D
Pharmacoeconomics; 2003; 21(5):305-14. PubMed ID: 12627984
[TBL] [Abstract][Full Text] [Related]
12. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Reginster JY
Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of preferences and quality of life in women with hip fractures.
Cranney AB; Coyle D; Hopman WM; Hum V; Power B; Tugwell PS
J Rheumatol; 2005 Dec; 32(12):2393-9. PubMed ID: 16331770
[TBL] [Abstract][Full Text] [Related]
14. [Absolute risk for fracture and WHO guideline. Economic analysis of pharmacotherapy for osteoporosis].
Harada A;
Clin Calcium; 2007 Jul; 17(7):1029-34. PubMed ID: 17607069
[TBL] [Abstract][Full Text] [Related]
15. Validity and reliability of the Italian version of the ECOS-16 questionnaire in postmenopausal women with prevalent vertebral fractures due to osteoporosis.
Salaffi F; Malavolta N; Cimmino MA; Di Matteo L; Scendoni P; Carotti M; Stancati A; Mulé R; Frigato M; Gutierrez M; Grassi W;
Clin Exp Rheumatol; 2007; 25(3):390-403. PubMed ID: 17631735
[TBL] [Abstract][Full Text] [Related]
16. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
17. Cost-effective osteoporosis intervention thresholds for Hong Kong postmenopausal women.
Kung AW; McGhee SM; Tsang SW; So J; Chau J
Hong Kong Med J; 2015 Dec; 21 Suppl 6():13-6. PubMed ID: 26645876
[No Abstract] [Full Text] [Related]
18. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
19. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
20. Costs and health effects of osteoporotic fractures.
Chrischilles E; Shireman T; Wallace R
Bone; 1994; 15(4):377-86. PubMed ID: 7917575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
